DK0626387T3 - Nukleosider og oligonukleotider med 2'-ethergrupper - Google Patents

Nukleosider og oligonukleotider med 2'-ethergrupper

Info

Publication number: DK0626387T3
Authority: DK; Denmark
Prior art keywords: alkyl; hydrogen; formula; radical; nucleosides
Prior art date: 1993-05-12

Application number

DK94810255T

Other languages

English (en)

Inventor

Pierre Dr Martin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-12

Filing date

1994-05-03

Publication date

1999-09-27

1994-05-03 Application filed by Novartis Ag filed Critical Novartis Ag

1999-09-27 Application granted granted Critical

1999-09-27 Publication of DK0626387T3 publication Critical patent/DK0626387T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
239000002777 nucleoside Substances 0.000 title 1
125000003835 nucleoside group Chemical group 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical group 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
229910052698 phosphorus Inorganic materials 0.000 abstract 1
239000011574 phosphorus Substances 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
125000000714 pyrimidinyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK94810255T 1993-05-12 1994-05-03 Nukleosider og oligonukleotider med 2'-ethergrupper DK0626387T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH146793		1993-05-12

Publications (1)

Publication Number	Publication Date
DK0626387T3 true DK0626387T3 (da)	1999-09-27

Family

ID=4211171

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94810255T DK0626387T3 (da)	1993-05-12	1994-05-03	Nukleosider og oligonukleotider med 2'-ethergrupper

Country Status (11)

Country	Link
US (1)	US5969116A (da)
EP (1)	EP0626387B1 (da)
JP (1)	JP4012579B2 (da)
CN (1)	CN1100728A (da)
AT (1)	ATE177430T1 (da)
AU (1)	AU687796B2 (da)
CA (1)	CA2123241C (da)
DE (1)	DE59407895D1 (da)
DK (1)	DK0626387T3 (da)
ES (1)	ES2128535T3 (da)
IL (3)	IL123330A (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789573A (en) *	1990-08-14	1998-08-04	Isis Pharmaceuticals, Inc.	Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
DE59510742D1 (de) *	1994-04-27	2003-08-14	Novartis Ag	Nukleoside und Oligonukleotide mit 2'-Ethergruppen
US6166197A (en) *	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0813539B1 (en) *	1995-03-06	2006-05-24	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US20110028350A1 (en) *	1995-12-15	2011-02-03	Affymetrix, Inc.	Photocleavable protecting groups
US6147205A (en) *	1995-12-15	2000-11-14	Affymetrix, Inc.	Photocleavable protecting groups and methods for their use
KR19990082476A (ko) *	1996-02-14	1999-11-25	하우스 한스 루돌프, 긴터 베아트리체	당-변형되어 갭이 형성된 올리고뉴클레오티드
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
AU3029797A (en) *	1996-06-06	1998-01-05	Novartis Ag	2'-substituted nucleosides and oligonucleotide derivatives
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
JP2000514095A (ja) *	1997-04-30	2000-10-24	アイシス・ファーマシューティカルス・インコーポレーテッド	生物学的利用能を向上するためのオリゴヌクレオチド
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US20040063618A1 (en) *	2002-09-30	2004-04-01	Muthiah Manoharan	Peptide nucleic acids having improved uptake and tissue distribution
US6093807A (en) *	1999-03-19	2000-07-25	Isis Pharmaceuticals, Inc.	Sugar-modified 7-deaza-7-substituted oligonucleotides
EP1325017A2 (en) *	2000-09-11	2003-07-09	Affymetrix, Inc.	Photocleavable protecting groups
US20030027169A1 (en) *	2000-10-27	2003-02-06	Sheng Zhang	One-well assay for high throughput detection of single nucleotide polymorphisms
DE10238722A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de)	2002-08-23	2004-03-11	Bayer Ag	Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de)	2002-08-23	2004-03-04	Bayer Ag	Alkyl-substituierte Pyrazolpyrimidine
WO2004043979A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
DE10320785A1 (de)	2003-05-09	2004-11-25	Bayer Healthcare Ag	6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en)	2003-05-09	2011-10-25	Boehringer Ingelheim International Gmbh	6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004001873A1 (de)	2004-01-14	2005-09-29	Bayer Healthcare Ag	Cyanopyrimidinone
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US7297686B2 (en) *	2004-11-16	2007-11-20	Hwang David L	Chromium complex with insulin-like activity
US8338093B2 (en) *	2004-12-31	2012-12-25	Affymetrix, Inc.	Primer array synthesis and validation
US7547775B2 (en)	2004-12-31	2009-06-16	Affymetrix, Inc.	Parallel preparation of high fidelity probes in an array format
PT1877070E (pt)	2005-05-05	2009-03-13	Antisense Pharma Gmbh	Utilização terapêutica de oligonucleótidos anti-sentido tgf-beta2
US8029579B2 (en)	2006-06-28	2011-10-04	COH Inc.	Fatty acid blends and uses therefor
US7820810B2 (en)	2007-03-19	2010-10-26	Isis Pharmaceuticals, Inc.	Process for the synthesis of 2′-O-substituted purine nulceosides
EP2222851B1 (en)	2007-11-20	2017-06-28	Ionis Pharmaceuticals, Inc.	Modulation of cd40 expression
JP5498392B2 (ja)	2007-11-30	2014-05-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
EP2247729B1 (en)	2008-02-11	2019-05-01	Phio Pharmaceuticals Corp.	Modified rnai polynucleotides and uses thereof
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
CN102143965A (zh)	2008-09-08	2011-08-03	贝林格尔.英格海姆国际有限公司	吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
EP2340309A2 (en)	2008-09-22	2011-07-06	Rxi Pharmaceuticals Corporation	Neutral nanotransporters
WO2010048585A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
CA2741294C (en)	2008-10-24	2018-04-24	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US9074211B2 (en)	2008-11-19	2015-07-07	Rxi Pharmaceuticals Corporation	Inhibition of MAP4K4 through RNAI
US9493774B2 (en)	2009-01-05	2016-11-15	Rxi Pharmaceuticals Corporation	Inhibition of PCSK9 through RNAi
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP3424939A1 (en) *	2009-03-02	2019-01-09	Alnylam Pharmaceuticals Inc.	Nucleic acid chemical modifications
PT2414363E (pt)	2009-03-31	2014-02-26	Boehringer Ingelheim Int	Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
AR077859A1 (es) *	2009-08-12	2011-09-28	Boehringer Ingelheim Int	Compuestos para el tratamiento de trastornos del snc
CN106074591B (zh)	2010-03-24	2020-01-14	菲奥医药公司	眼部症候中的rna干扰
EP2550000A4 (en)	2010-03-24	2014-03-26	Advirna Inc	RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING
BR112012024049A2 (pt)	2010-03-24	2017-03-01	Rxi Pharmaceuticals Corp	interferência de rna em indicações dérmicas e fibróticas
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
EP3091027B1 (en)	2010-04-28	2018-01-17	Ionis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (en)	2010-04-28	2016-09-07	Ionis Pharmaceuticals, Inc.	Modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
UA110347C2 (uk)	2010-08-12	2015-12-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
EP2453017A1 (en)	2010-11-12	2012-05-16	Antisense Pharma GmbH	Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102993255B (zh) *	2011-09-19	2016-02-10	上海兆维科技发展有限公司	2’-o-(2-甲氧乙基)-5-甲基尿苷和2’-o-(2-甲氧乙基)-5-甲基胞苷及其衍生物的制备及其纯化方法
WO2014178082A1 (en) *	2013-05-03	2014-11-06	Council Of Scientific & Industrial Research	Novel 2'/3'/5'-(r/s)-serinyl functionalized oligonucleotides
JP6694382B2 (ja)	2013-06-21	2020-05-13	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	標的核酸を調節するための組成物および方法
CN106061488B (zh)	2013-12-02	2021-04-09	菲奥医药公司	癌症的免疫治疗
US11279934B2 (en)	2014-04-28	2022-03-22	Phio Pharmaceuticals Corp.	Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
KR102506169B1 (ko)	2014-09-05	2023-03-08	피오 파마슈티칼스 코프.	Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11001845B2 (en)	2015-07-06	2021-05-11	Phio Pharmaceuticals Corp.	Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
CN109563509B (zh)	2015-10-19	2022-08-09	菲奥医药公司	靶向长非编码rna的减小尺寸的自递送核酸化合物
JP6853537B2 (ja)	2016-02-17	2021-03-31	国立大学法人東京工業大学	人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
JP7167059B2 (ja)	2017-04-19	2022-11-08	フィオファーマシューティカルズコーポレーション	核酸化合物の局所送達
KR102724871B1 (ko) *	2017-08-18	2024-10-31	애질런트 테크놀로지스, 인크.	올리고뉴클레오티드의 친화성 정제를 위한 오르토에스터 조성물
CN111819285B (zh)	2018-01-09	2024-08-09	希博斯美国有限公司	防碎基因和突变
CN111868244A (zh)	2018-03-20	2020-10-30	国立大学法人东京工业大学	降低了毒性的反义寡核苷酸
JPWO2023027065A1 (da)	2021-08-24	2023-03-02
CN118076620A (zh)	2021-09-30	2024-05-24	日产化学株式会社	2’修饰嘧啶核苷的制造方法
CN116606336B (zh) *	2022-04-02	2025-09-12	思合基因(北京)生物科技有限公司	高稳定性和亲和力的2′-o-取代核苷及其应用
EP4682155A1 (en)	2023-03-15	2026-01-21	Nissan Chemical Corporation	Production methods for 2'-o-modified adenosine phosphoramidite and intermediate thereof
JPWO2025005265A1 (da) *	2023-06-30	2025-01-02
WO2025047855A1 (ja)	2023-08-29	2025-03-06	月島機械株式会社	横型回転式乾燥機

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (en) *	1986-10-28	1990-09-19	The Johns Hopkins University	Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
EP0402402B1 (en) *	1988-02-26	1995-12-27	Worcester Foundation For Biomedical Research, Inc.	Inhibition of htlv-iii by exogenous oligonucleotides
DK0942000T3 (da) *	1989-10-24	2004-11-01	Isis Pharmaceuticals Inc	2'-modificerede oligonukleotider
US5212295A (en) *	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
HUT63170A (en) *	1990-01-11	1993-07-28	Isis Pharmaceuticals Inc	Process and composition for detecting and modifying rna activity and gene expression
DE69133511T2 (de) *	1990-08-13	2006-09-28	Isis Pharmaceuticals, Inc., Carlsbad	Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
KR940703846A (ko) *	1991-12-24	1994-12-12	비. 린네 파샬	갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
JP3015464B2 (ja) *	1992-07-23	2000-03-06	アイシス・ファーマシューティカルス・インコーポレーテッド	新規２’−０−アルキルヌクレオシドおよびホスホロアミダイトの製造法およびその使用

1994
- 1994-05-03 DK DK94810255T patent/DK0626387T3/da active
- 1994-05-03 ES ES94810255T patent/ES2128535T3/es not_active Expired - Lifetime
- 1994-05-03 DE DE59407895T patent/DE59407895D1/de not_active Expired - Lifetime
- 1994-05-03 EP EP94810255A patent/EP0626387B1/de not_active Expired - Lifetime
- 1994-05-03 AT AT94810255T patent/ATE177430T1/de active
- 1994-05-10 CA CA002123241A patent/CA2123241C/en not_active Expired - Lifetime
- 1994-05-10 IL IL12333094A patent/IL123330A/xx not_active IP Right Cessation
- 1994-05-10 IL IL10960594A patent/IL109605A/xx not_active IP Right Cessation
- 1994-05-11 AU AU63044/94A patent/AU687796B2/en not_active Expired
- 1994-05-11 CN CN94105715A patent/CN1100728A/zh active Pending
- 1994-05-12 JP JP12295794A patent/JP4012579B2/ja not_active Expired - Lifetime
1995
- 1995-06-02 US US08/459,434 patent/US5969116A/en not_active Expired - Fee Related
1998
- 1998-02-17 IL IL12333098A patent/IL123330A0/xx unknown

Also Published As

Publication number	Publication date
US5969116A (en)	1999-10-19
EP0626387A1 (de)	1994-11-30
EP0626387B1 (de)	1999-03-10
ATE177430T1 (de)	1999-03-15
AU687796B2 (en)	1998-03-05
JP4012579B2 (ja)	2007-11-21
CA2123241A1 (en)	1994-11-13
IL123330A0 (en)	1998-09-24
DE59407895D1 (de)	1999-04-15
CN1100728A (zh)	1995-03-29
ES2128535T3 (es)	1999-05-16
AU6304494A (en)	1994-11-17
IL123330A (en)	1999-12-31
IL109605A0 (en)	1994-08-26
CA2123241C (en)	2007-02-13
IL109605A (en)	1999-12-31
JPH072889A (ja)	1995-01-06

Publication	Publication Date	Title
ATE177430T1 (de)	1999-03-15	Nukleoside und oligonukleotide mit 2'- ethergruppen
DE69815342D1 (de)	2003-07-10	Sulfonatfreie cyaninfarbstoffe zur markierung von nukleosiden und nukleotiden
NO303543B1 (no)	1998-07-27	Nukleosid-5'-trifosfat og fosforamiditt samt anvendelser derav
DE3751947D1 (de)	1996-12-12	Nucleosidderivate und ihre Verwendung in der Oligonucleotid-Synthese
DE3670293D1 (de)	1990-05-17	Adenosin-nukleosid-derivate, ihre herstellung und biologische verwendung.
EP0679657A3 (de)	1996-04-10	Nukleoside und Oligonukleotide mit 2'-Ethergruppen.
ES2106684A1 (es)	1997-11-01	2-hidroxifeniltriazinas.
ES2156994T3 (es)	2001-08-01	Sustratos para beta-lactamasa y usos de estos sustratos.
DE69324923D1 (de)	1999-06-17	Antiretrovirale, enantiomere Nukleotid-Analoge
MX166257B (es)	1992-12-24	Composicion de revestimiento que contiene grupos de carbamato de hidroxialquilo
CA2159710A1 (en)	1994-10-27	Organosilicon-Containing Materials Useful for Biomedical Devices
NO178500C (no)	1996-04-10	Spikamycinderivater, mellomprodukt samt antitumormiddel
DK0816368T3 (da)	2003-05-05	Kemisk phosphorylering af oligonukleotider og reaktanter anvendt dertil
DE69621229D1 (de)	2002-06-20	Antivirale triazazyklododecane
TW368519B (en)	1999-09-01	Anhydrous fluorescent whitening agent composition
GR3019075T3 (en)	1996-05-31	Inhibitor of herpes simplex viral thymidine kinase
EP0350804A3 (en)	1990-12-19	Process for the preparation of halosilanes
YU48991B (sh)	2003-04-30	POSTUPAK ZA DOBIJANJE Гџ ANOMEROM OBOGAĆENOG NUKLEOZIDA